Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sean Miran

Family Medicine Madison, WI Doctor of Osteopathy

NPI 1780785725 CMS profile 216604

202 S Park St, Madison, WI 53715

Open in the dashboard

General payments

$1,157

12 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sean Miran of Madison, WI is reported in the CMS Open Payments database as having received $1,157 across 12 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $488 4
2023 General $91 1
2021 General $119 2
2019 General $458 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sean Miran
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Sean Miran were reported at $488. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Sean Miran Family Medicine median Middle half National median
2019 $458 $150 $41–$543 $163
2020 $0 $120 $32–$415 $114
2021 $119 $137 $35–$551 $132
2022 $0 $137 $37–$512 $149
2023 $91 $149 $42–$545 $160
2024 $0 $156 $44–$560 $164
2025 $488 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alexion Pharmaceuticals, Inc. $363 3 payments
  2. GlaxoSmithKline, LLC. $327 4 payments
  3. Novo Nordisk Inc $119 1 payment
  4. Celgene Corporation $119 1 payment
  5. Pfizer Inc. $116 1 payment
  6. Novartis Pharmaceuticals Corporation $113 1 payment
  7. Retrophin, Inc. $0 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,156 11 payments
  2. Education $0 1 payment
Products named General payments · program years 2019–2025
  1. ULTOMIRIS $242 2 payments
  2. AREXVY Respiratory $125 1 payment
  3. Wegovy $119 1 payment
  4. Otezla $119 1 payment
  5. PREVNAR - 13 $116 1 payment
  6. ENTRESTO $113 1 payment
  7. TRELEGY ELLIPTA $110 2 payments
  8. AREXVY Respiratory $91 1 payment
  9. Cholbam $0 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 119 drugs

Part D claims

5,316

Median for Family Practice: 1,826

Drug cost

$571,347

Median for Family Practice: $120,094

Branded share of claims

24.8%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trulicity Dulaglutide Brand 57 $78,625
Jardiance Empagliflozin Brand 71 $77,124
Mounjaro Tirzepatide Brand 59 $65,434
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 34 $35,282
Eliquis Apixaban Brand 33 $31,859
Farxiga Dapagliflozin Propanediol Brand 55 $31,089
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 51 $26,861
Ozempic Semaglutide Brand 22 $26,408
Entresto Sacubitril/Valsartan Brand 32 $25,770
Breo Ellipta Fluticasone/Vilanterol Brand 22 $13,241

The 10 drugs with the highest cost, of 119 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$25,045

Medicare's payments for the services billed

Medicare patients

124

Average age 70

Services billed

351

44 women, 80 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 27%
Diabetes 20%
Ischemic heart disease 18%
Chronic kidney disease 15%
Depression 15%
Atrial fibrillation 12%
COPD 12%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

12 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record